Trials / Suspended
SuspendedNCT00909558
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
A Phase I Open Label, Single Site, Safety and Efficacy Study of the Effects of Autologous Natural Killer and Natural Killer T Cell Immunotherapy on Malignant Disease
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Envita Medical Center, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.
Conditions
- Breast Cancer
- Glioma
- Hepatocellular Cancer
- Squamous Cell Lung Cancer
- Pancreatic Cancer
- Colon Cancer
- Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous Natural Killer / Natural Killer T Cell Immunotherapy | The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous. The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2010-06-01
- First posted
- 2009-05-28
- Last updated
- 2010-02-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00909558. Inclusion in this directory is not an endorsement.